Opus Genetics (IRD) 10-Q2022 Q1 Quarterly report

Filed: 13 May 22, 9:01am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Bad

New words: adjunctive, analytical, APX, assistance, baseline, blurry, burning, cancer, Committee, comparison, complex, component, consulting, daily, deferral, discomfort, expand, expanding, exposure, filer, government, healthy, hepatic, HQ, hydrochloride, indexation, instillation, invitation, Jay, lab, led, loan, long, maintenance, masked, meaningful, medical, mentioned, mg, MIRA, mm, nonstatutory, older, ongoing, pain, panel, payroll, PD, Pepose, policy, protecting, refractive, rental, response, returned, returning, school, shipping, showed, shown, site, sixteen, slight, stinging, Supplementary, team, therapy, topline, transparency, unissued, vital, wAMD, young

Removed: absence, absent, accelerated, accredited, achieved, acquired, acquirer, adjusted, affecting, allocated, alternative, America, American, amortization, applied, approximate, assessed, automatic, bifurcation, bound, Building, calculated, Certified, charged, CIC, closed, convert, corporation, counterparty, default, Delaware, demand, DemandTM, designated, determination, dilate, discharged, discount, divided, earliest, embedded, entitled, existed, extinguished, feasibility, feet, fourth, framework, front, gradual, host, Hundred, incorporation, Institute, investment, IPO, irrevocably, iv, judgment, July, jurisdiction, leasing, licensed, low, meeting, member, merge, methodology, Mezz, nearby, nearest, objective, OCUP, Organization, owed, par, Payoff, permit, pharmacological, Practice, premium, prepay, proxy, qualifying, Razor, reached, receipt, redemption, release, rely, removed, Reorganization, retroactive, REXN, rounded, satisfaction, sector, separated, separately, September, set, square, successor, surrender, symbol, tangible, technical, technological, ticker, traded, unconditionally, unpaid, utilized, voting

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

IRD similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)

In connection with the Quarterly Report on Form 10-Q for the quarter ended March 31, 2022 (the “Report”) of Ocuphire Pharma, Inc., a Delaware corporation (the “Company”) as filed with the Securities and Exchange Commission, Mina Sooch, as Chief Executive Officer of the Company, and Amy Rabourn, as Vice President of Finance of the Company, each hereby certifies, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that to the best of her knowledge and belief:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)); and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

/s/ Mina Sooch
Mina Sooch
Chief Executive Officer
(Principal Executive Officer)

/s/ Amy Rabourn
Amy Rabourn
Vice President of Finance
(Principal Accounting Officer)

Dated: May 13, 2022